HLA抗体评估之路：勿依赖平均荧光强度（MFI）。
The Road to HLA Antibody Evaluation: Do Not Rely on MFI.
作者信息
Sullivan H C, Liwski R S, Bray R A, Gebel H M
机构信息
Department of Pathology, Emory University Hospital, Atlanta, GA.
Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
出版信息
Am J Transplant. 2017 Jun;17(6):1455-1461. doi: 10.1111/ajt.14229. Epub 2017 Mar 17.
Abstract
Technological advances in HLA laboratory testing undoubtedly improved the sensitivity and specificity of HLA antibody assessment but not without introducing a set of challenges regarding data interpretation. In particular, the introduction of solid-phase single-antigen bead (SAB) antibody assessment brought the belief that mean fluorescence intensity (MFI) was a quantifiable value. As such, MFI levels heavily influenced HLA antibody reporting, monitoring, and clinical practice. However, given that SAB testing was neither intended for nor approved to be quantifiable, is the use of MFI in current clinical and laboratory practice valid? What, if anything, does this numerical value actually reveal about the pathogenic potential of the antibody? What are the pitfalls and caveats associated with reporting MFI? Herein, we travel the road to HLA antibody assessment and explore the reliability of MFI values to make clinical decisions.
摘要
人类白细胞抗原（HLA）实验室检测技术的进步无疑提高了HLA抗体评估的敏感性和特异性，但在数据解读方面也带来了一系列挑战。特别是，固相单抗原珠（SAB）抗体评估方法的引入，让人认为平均荧光强度（MFI）是一个可量化的值。因此，MFI水平严重影响了HLA抗体的报告、监测及临床实践。然而，鉴于SAB检测并非旨在用于量化，也未获批准可进行量化，那么在当前临床和实验室实践中使用MFI是否有效？这个数值究竟能揭示抗体的致病潜力吗？报告MFI存在哪些陷阱和注意事项？在此，我们踏上HLA抗体评估之路，探讨MFI值用于临床决策的可靠性。
相似文献
1
The Road to HLA Antibody Evaluation: Do Not Rely on MFI.HLA抗体评估之路：勿依赖平均荧光强度（MFI）。
Am J Transplant. 2017 Jun;17(6):1455-1461. doi: 10.1111/ajt.14229. Epub 2017 Mar 17.
2
Technical Limitations of the C1q Single-Antigen Bead Assay to Detect Complement Binding HLA-Specific Antibodies.用于检测补体结合HLA特异性抗体的C1q单抗原珠试验的技术局限性
Transplantation. 2017 Jun;101(6):1206-1214. doi: 10.1097/TP.0000000000001270.
3
Getting on target: Development of the novel, prozone-resistant, dual antibody rapid test (DART) for the LABScreen single antigen bead (SAB) assay.有的放矢：新型、抗前带效应、双抗体快速检测（DART）试剂用于 LABScreen 单抗原珠（SAB）检测试剂的开发。
Hum Immunol. 2019 Jul;80(7):468-477. doi: 10.1016/j.humimm.2019.04.017. Epub 2019 Apr 28.
4
Comparative analysis of Luminex-based donor-specific antibody mean fluorescence intensity values with complement-dependent cytotoxicity & flow crossmatch results in live donor renal transplantation.基于Luminex的供者特异性抗体平均荧光强度值与补体依赖细胞毒性及流式交叉配型结果在活体供者肾移植中的对比分析
Indian J Med Res. 2017 Feb;145(2):222-228. doi: 10.4103/ijmr.IJMR_222_16.
5
A modeling approach for mean fluorescence intensity value harmonization and cutoff prediction for luminex single antigen bead assays of two different vendors.一种用于两种不同供应商的 Luminex 单抗原珠分析的平均荧光强度值协调和截断预测的建模方法。
HLA. 2023 Nov;102(5):557-569. doi: 10.1111/tan.15082. Epub 2023 May 2.
6
Understanding solid-phase HLA antibody assays and the value of MFI.了解固相 HLA 抗体检测及平均荧光强度（MFI）的价值。
Hum Immunol. 2017 Jul-Aug;78(7-8):471-480. doi: 10.1016/j.humimm.2017.05.007. Epub 2017 May 30.
7
Role of crossmatch testing when Luminex-SAB is negative in renal transplantation.当Luminex-SAB在肾移植中呈阴性时交叉配型检测的作用
Pol Przegl Chir. 2018 Feb 28;90(1):41-46. doi: 10.5604/01.3001.0011.5959.
8
Interpretation of HLA single antigen bead assays.HLA 单抗原珠检测的解读。
Transplant Rev (Orlando). 2013 Oct;27(4):108-11. doi: 10.1016/j.trre.2013.07.001. Epub 2013 Aug 17.
9
Assessment of Rapid Optimized 96-well Tray Flow Cytometric Crossmatch (Halifax-FCXM) with Luminex Single Antigen Test. Halifax-FCXM 流式细胞仪快速优化 96 孔板交叉配型与 Luminex 单抗原检测的评估
Hum Immunol. 2021 Apr;82(4):302-308. doi: 10.1016/j.humimm.2021.02.003. Epub 2021 Mar 18.
10
Low median fluorescence intensity could be a nonsafety concept of immunologic risk evaluation in patients with shared molecular eplets in kidney transplantation.在肾移植中，共享分子表位的患者中低中位荧光强度可能是非免疫风险评估的安全概念。
Hum Immunol. 2012 May;73(5):522-5. doi: 10.1016/j.humimm.2012.02.020. Epub 2012 Mar 6.
引用本文的文献
1
Machine learning enhanced immunologic risk assessments for solid organ transplantation.机器学习增强实体器官移植的免疫风险评估。
Sci Rep. 2025 Mar 7;15(1):7943. doi: 10.1038/s41598-025-92147-w.
2
Follow-up biopsies with microvascular inflammation and persistent donor specific antibodies identify ongoing rejection in pediatric kidney transplant recipients.伴有微血管炎症和持续性供体特异性抗体的随访活检可识别小儿肾移植受者的持续性排斥反应。
Pediatr Nephrol. 2025 Jul;40(7):2375-2382. doi: 10.1007/s00467-025-06671-y. Epub 2025 Jan 28.
3
Allosensitisation in NHP results in cross-reactive anti-SLA antibodies not detected by a lymphocyte-based flow cytometry crossmatch.在非人类灵长类动物中，同种异体致敏会导致淋巴细胞交叉配型流式细胞术无法检测到的交叉反应性抗 SLA 抗体。
HLA. 2024 Jul;104(1):e15599. doi: 10.1111/tan.15599.
4
Translation of therapeutic strategies to modulate B cell reponses from non-human primate models to human kidney transplantation.将调节B细胞反应的治疗策略从非人灵长类动物模型转化至人类肾移植
Front Transplant. 2023 Apr 19;2:1176796. doi: 10.3389/frtra.2023.1176796. eCollection 2023.
5
Crossmatch assays in transplantation: Physical or virtual?: A review.移植中的交叉配型检测：物理检测还是虚拟检测？：一篇综述。
Medicine (Baltimore). 2023 Dec 15;102(50):e36527. doi: 10.1097/MD.0000000000036527.
6
Impact of allele-specific anti-human leukocyte antigen class I antibodies on organ allocation.针对人类白细胞抗原 I 类抗体的等位基因特异性对器官分配的影响。
Am J Transplant. 2023 Sep;23(9):1388-1400. doi: 10.1016/j.ajt.2023.05.021. Epub 2023 May 29.
7
Principles of Virtual Crossmatch Testing for Kidney Transplantation.肾移植虚拟交叉配型检测原则
Kidney Int Rep. 2022 Mar 15;7(6):1179-1188. doi: 10.1016/j.ekir.2022.03.006. eCollection 2022 Jun.
8
Prevalance of Anti-HLA antibodies in parous female blood donors: A pilot study from tertiary care hospital of North India.经产妇献血者中抗人白细胞抗原抗体的流行率：来自印度北部三级医院的一项初步研究。
Asian J Transfus Sci. 2021 Jan-Jun;15(1):16-20. doi: 10.4103/ajts.AJTS_30_19. Epub 2021 Jun 12.
9
Rebound and overshoot of donor-specific antibodies to human leukocyte antigens (HLA) during desensitization with plasma exchanges in hematopoietic progenitor cell transplantation: A case report.在造血祖细胞移植中，通过血浆置换进行脱敏时，人白细胞抗原（HLA）供体特异性抗体的反弹和超调：病例报告。
Transfusion. 2021 Jun;61(6):1980-1986. doi: 10.1111/trf.16411. Epub 2021 Apr 26.
10
A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.抗白介素 6 抗体克拉屈珠单抗治疗晚期抗体介导的肾移植排斥反应的随机临床试验。
J Am Soc Nephrol. 2021 Mar;32(3):708-722. doi: 10.1681/ASN.2020071106. Epub 2020 Dec 18.
本文引用的文献
1
Role of Pretransplant Complement-fixing Donor-specific Antibodies Identified by C1q Assay in Kidney Transplantation.通过C1q检测鉴定的移植前补体结合供者特异性抗体在肾移植中的作用。
Transplant Proc. 2016 Apr;48(3):756-60. doi: 10.1016/j.transproceed.2015.12.116.
2
Clinically relevant interpretation of solid phase assays for HLA antibody.HLA抗体固相检测的临床相关解读
Curr Opin Organ Transplant. 2016 Aug;21(4):453-8. doi: 10.1097/MOT.0000000000000326.
3
Immunological risk assessment and human leukocyte antigen antibody testing in kidney transplantation.肾移植中的免疫风险评估与人类白细胞抗原抗体检测
Indian J Nephrol. 2016 Mar-Apr;26(2):80-5. doi: 10.4103/0971-4065.167275.
4
Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.初发供者特异性 HLA 抗体获得 C3d 结合活性与未致敏儿童肾移植受者的移植物丢失相关。
Am J Transplant. 2016 Jul;16(7):2106-16. doi: 10.1111/ajt.13700. Epub 2016 Feb 16.
5
IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury.IgG供者特异性抗人HLA抗体亚类与肾移植抗体介导的损伤
J Am Soc Nephrol. 2016 Jan;27(1):293-304. doi: 10.1681/ASN.2014111120. Epub 2015 Aug 20.
6
The Synergistic Effect of Class II HLA Epitope-Mismatch and Nonadherence on Acute Rejection and Graft Survival.II类人类白细胞抗原表位错配与不依从性对急性排斥反应和移植物存活的协同作用
Am J Transplant. 2015 Aug;15(8):2197-202. doi: 10.1111/ajt.13341. Epub 2015 Jun 11.
7
Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information.评估抗体强度：平均荧光强度（MFI）、C1q和滴度信息的比较。
Am J Transplant. 2015 Sep;15(9):2421-30. doi: 10.1111/ajt.13295. Epub 2015 Apr 30.
8
Deciphering allogeneic antibody response against native and denatured HLA epitopes in organ transplantation.解析器官移植中针对天然和变性 HLA 表位的同种异体抗体反应。
Eur J Immunol. 2015 Jul;45(7):2111-21. doi: 10.1002/eji.201445340. Epub 2015 Apr 28.
9
The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection.完美风暴：移植排斥反应中的HLA抗体、补体、Fcγ受体与内皮细胞
Trends Mol Med. 2015 May;21(5):319-29. doi: 10.1016/j.molmed.2015.02.004. Epub 2015 Mar 20.
10
Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: prevalence, relevance, and impact on organ allocation.致敏肾移植受者的变性 I 类人类白细胞抗原抗体：流行率、相关性及其对器官分配的影响。
Transplantation. 2014 Oct 15;98(7):738-44. doi: 10.1097/TP.0000000000000229.
Zotero 插件